Study: Pneumococcal Vaccine for Middle-aged and Older Adults Increases Risk for Pneumonia and Death

Share it with your friends Like

Thanks! Share it with your friends!

Close

By AdminM

Senior-Woman-Vaccine

by Brian Shilhavy
Editor, Health Impact News

Medical professionals from Spain have just published a study (April 2018) on the 13-valent pneumococcal conjugate vaccine (PCV13) that is routinely given to older adults to protect against pneumonia. The study was published in the journal BMC Infectious Diseases.

The PCV13 vaccine has been available since 2012, when it was approved by the FDA. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) recommends the PCV13 vaccine for persons aged 19–64 years who have high-risk conditions (mainly anatomical or functional asplenia and …read more

Source: Health Impact News

    

  • Rating:
  • Views:210 views
  • Categories: Health